Equillium (EQ) Cash from Financing Activities (2018 - 2026)
Equillium (EQ) posted quarterly Cash from Financing Activities of $35.3 million for Q1 2026, up 38741.76% year-over-year from N/an in Q1 2025, and up 12389.75% quarter-over-quarter from $283000.0 in Q4 2025.
Powered by 
Analysis
Equillium (EQ) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Cash from Financing Activities for 9 consecutive years, with $35.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 38741.76% year-over-year to $35.3 million; the TTM figure through Mar 2026 stood at $65.7 million (up 26929.63% YoY), while the FY2025 annual figure was $30.4 million, up 18453.05% from the prior year.
- Cash from Financing Activities grew to $35.3 million in Q1 2026 per EQ's latest filing, from $283000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $35.3 million in Q1 2026 and bottomed at -$7.6 million in Q2 2023.
- Historically, Cash from Financing Activities has averaged $5.0 million across 5 years, with a median of $73000.0 in 2024.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 702.67% — and 2026, when it jumped 38741.76%.
- Equillium's Cash from Financing Activities stood at -$1.4 million in 2022, then jumped by 105.83% to $79000.0 in 2023, then declined by 7.59% to $73000.0 in 2024, then surged by 287.67% to $283000.0 in 2025, then soared by 12389.75% to $35.3 million in 2026.
- Business Quant data shows EQ's Cash from Financing Activities at $35.3 million in Q1 2026, $283000.0 in Q4 2025, and $30.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - | 42,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 42,000.00 |
| Mar 31, 2026 | 35.35 Mn |
| Dec 31, 2025 | 283,000.00 |
| Sep 30, 2025 | 30.07 Mn |
| Jun 30, 2025 | -16,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Dec 31, 2024 | 73,000.00 |
| Dec 31, 2023 | 79,000.00 |
| Sep 30, 2023 | -260,000.00 |
| Jun 30, 2023 | -7.62 Mn |
| Mar 31, 2023 | -1.43 Mn |
| Dec 31, 2022 | -1.36 Mn |
| Dec 31, 2021 | 225,000.00 |
| Sep 30, 2021 | 174,000.00 |
| Jun 30, 2021 | 698,000.00 |
| Mar 31, 2021 | 29.96 Mn |
| Dec 31, 2020 | 11,000.00 |
| Sep 30, 2020 | 53.06 Mn |
| Jun 30, 2020 | 96,000.00 |
| Mar 31, 2020 | 775,000.00 |